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Primary hyperparathyroidism is the most common cause of hypercalcemia in the outpatient population. This condition is usually
the result of a single hyperfunctioning parathyroid gland. Targeted parathyroidectomy guided by intraoperative parathyroid
hormone monitoring (IPM) through a small cervical incision has replaced traditional bilateral neck exploration (BNE) as the
initial approach in the surgical treatment of primary hyperparathyroidism at many medical centers worldwide. Preoperative
sestamibi-technetium 99m scintigraphy serves as an important prerequisite for successful targeted parathyroidectomy. Single-
photon emission computed tomography (SPECT) and CT fusion, however, is a recent imaging technique that provides a three-
dimensional functional image with advanced contrast resolution to greatly improve preoperative localization of parathyroid
tumors.
1.Introduction
Primary hyperparathyroidism is the most common cause
of hypercalcemia in the outpatient population. The delicate
balance of calcium homeostasis in the human body has long
been appreciated. Serum elevation of this mineral secondary
tooverproductionofparathyroidhormoneisassociatedwith
fatigue, musculoskeletal pain, weakness, polyuria, nocturia,
renal stones, memory loss, constipation, polydipsia, heart-
burn, and depression. At the present time, most patients
with hyperparathyroidism do not present with symptoms
of hypercalcemia, but rather are identiﬁed on routine bio-
chemical screening. The underlying cause of primary hyper-
parathyroidism is usually a single parathyroid adenoma in
85–96% of cases while less frequent causes include double
adenoma, parathyroid hyperplasia, and parathyroid carci-
noma. Parathyroidectomy is indicated in all patients with
symptomatic hyperparathyroidism and in those individuals
with asymptomatic hyperparathyroidism that satisﬁes cer-
tain consensus criteria. These most recent guidelines include
a serum calcium concentration >1.0mg/dL above the upper
limit of normal, creatinine clearance <60mL/min, bone
density >2.5standard deviations below standard reference
values for sex-matched peak bone mass at any site (T-score
<-2.5), age <50 years old, inability or unwillingness to be
followed, or a severe psychoneurologic disorder [1].
Since the ﬁrst attempted parathyroidectomy in 1925 by
Mandl, the surgical treatment for primary hyperparathy-
roidism has undergone a gradual evolution [2]. The large
collar incision has been replaced by a very small 2–4-
centimeter lower neck incision, and bilateral four-gland
neck exploration has largely been supplanted by focused
single-gland excision with biochemical conﬁrmation of a
successful operation in the operating room. In addition, the
diagnostic technology available for parathyroid localization
has improved tremendously over the years, allowing elusive
andectopicabnormalparathyroidglandstobeidentiﬁedand
localized in advance of parathyroid surgery, thus decreasing
risk of unsuccessful surgical intervention and the need
for reoperation. Together, preoperative imaging combined
with intraoperative parathyroid hormone monitoring (IPM)
allow for successful surgical outcomes and treatment of
primary hyperparathyroidism at rates comparable to those
of conventional bilateral neck exploration (BNE) [3–7].2 International Journal of Molecular Imaging
While sestamibi-technetium 99m scintigraphy (sestamibi)
has been considered a mainstay or essential component of
focused parathyroidectomy often complemented by ultra-
sound (US), single-photon emission computed tomography
(SPECT) imaging is a more recent advancement in preoper-
ative parathyroid localization that may have further impact
in the planning and success of targeted parathyroidectomy.
2. Anatomy, Embryology, andPathology of
the ParathyroidGlands
Eﬀective image interpretation and operative planning can-
not commence without full understanding of parathyroid
anatomy and its embryology. While four parathyroid glands
are found in the majority of humans, cadaver studies
demonstrated a 13% presence of supernumerary glands
and a 3% prevalence of only three parathyroid glands [8].
At four weeks of embryologic development, the superior
parathyroid glands originate from the fourth branchial
pouch and undergo very little migration whereas the inferior
parathyroid glands descend from the third branchial pouch
to more varied locations along with the thymus. These
paired superior and inferior parathyroid glands are typically
symmetric in location bilaterally. In about 80% of cases, the
superior and inferior parathyroid glands receive their blood
supply from the inferior thyroid artery [8, 9].
The superior parathyroid glands are often found on the
posteromedial aspect of the thyroid’s superior poles approxi-
matelyonecentimeterabovetheintersectionoftherecurrent
laryngeal nerve and inferior thyroid artery at the level of
the cricoid cartilage. Since these glands undergo limited
migration during embryologic development, they are rarely
ectopic; however, when they do occupy ectopic domains the
positions include the tracheoesophageal groove, posterior
mediastinum, retroesophageal space, retropharyngeal space,
and intrathyroid locations. The inferior parathyroid glands
are typically located on the posterolateral surface of the
inferior poles of the thyroid gland below the intersection
of the recurrent laryngeal nerve and inferior thyroid artery.
In about 80% of the population, the inferior parathyroid
glands reside anteriorly, inferiorly, or laterally within 2cm
of the inferior pole of the thyroid gland [8, 9]. In the
20% of patients that have an ectopic inferior parathyroid
gland, the most common location is within the true sheath
of the thymus (15%); less frequently they are found in
the intrathyroidal location (1–4%), anterior mediastinum,
submandibular location, tracheoesophageal groove, retroe-
sophageal space, and carotid sheath [8, 9].
The underlying pathology of primary hyperparathy-
roidism is most commonly a single parathyroid adenoma.
This benign encapsulated neoplasm accounts for 85–96%
of cases of primary hyperparathyroidism. Although most
have a single aﬀected gland, two aﬀected glands (double
adenoma) may be found in 2 to 5% of patients with
primary hyperparathyroidism. Parathyroid hyperplasia is
caused by an increase of parenchymal mass within all the
parathyroid glands, and it accounts for 4–15% of cases.
The incidence of hyperplasia increases in patients with
multiple endocrine neoplasia (MEN) and non-MEN familial
isolated hyperparathyroidism. Parathyroid hyperplasia is
treated either by subtotal (3.5 gland) parathyroidectomy or
total parathyroidectomy with autotransplantation. Parathy-
roid carcinoma is a very rare, indolent growing malignant
neoplasm of parenchymal cells responsible for 1–5% of all
primary hyperparathyroidism cases [10].
3. PrimaryHyperparathyroidism
Primary hyperparathyroidism results from the overpro-
duction of parathyroid hormone (PTH) by one or more
hyperfunctioning parathyroid glands that usually causes
hypercalcemia. Current widespread use of serum channel
autoanalyzershasallowedfortheearlierdiagnosisofprimary
hyperparathyroidism in patients without the manifestation
of clinical symptoms [11]. As the most common cause of
hypercalcemia in the outpatient setting, its incidence in
the general population ranges from 0.1 to 0.3%, occurring
more frequently in women than men, and in those with
advanced age [12–14]. Known risk factors for primary
hyperparathyroidism include abnormalities of the PRAD1,
MEN1, and HRPT2 genes that encode for cyclin D1, menin,
and paraﬁbromin, respectively. Radiation exposure to the
neck, especially during childhood, is also associated with
development of primary hyperparathyroidism [15–18].
The classic description of kidney “stones,” painful
“bones,” abdominal “groans,” lethargic “moans,” and psy-
chiatric “overtones” associated with primary hyperparathy-
roidism are now infrequently encountered in Western
populations. In these parts of the world, patients with
primary hyperparathyroidism present most commonly with
abnormal biochemical results and not the “textbook” man-
ifestations of primary hyperparathyroidism and hypercal-
cemia such as fatigue, musculoskeletal pain, polyuria, noc-
turia, polydipsia, constipation, heartburn, memory loss, and
depression. Nonetheless, up to 80% of patients currently
present with nonspeciﬁc symptoms of depression, fatigue,
and lethargy, and they often are considered asymptomatic.
Of note, hypertension and nephrolithiasis are the most com-
monly associated preoperative conditions found in patients
with primary hyperparathyroidism [19, 20].
Biochemical diagnosis and conﬁrmation of primary
hyperparathyroidism is made by demonstrating elevated
total serum or ionized calcium levels, and high intact PTH
levels in the setting of normal renal function. In primary
hyperparathyroidism, vitamin D metabolism is typically
characterized by low plasma levels of 25-hydroxyvitamin
D and high plasma levels of 1,25-dihydroxyvitamin D.
Twenty-four-hour urine calcium collection is also helpful
to exclude the diagnosis of benign familial hypocalciuric
hypercalcemia (BFHH). A rare, autosomal dominant con-
dition identiﬁed in patients with a family history of hyper-
calcemia and decreased urine calcium excretion since birth,
BFHH biochemically mimics primary hyperparathyroidism
by revealing elevated calcium and PTH levels, but with
low levels of urinary calcium (less than 50mg/24 hours).
Similarly, the urinary calcium-to-creatinine clearance ratio
in BFHH is less than 0.01 whereas in patients with primaryInternational Journal of Molecular Imaging 3
hyperparathyroidism the ratio is greater than 0.02. However,
BFHH is a benign condition that cannot be corrected by
parathyroidectomy.
Parathyroidectomy is performed in all patients with
a secure diagnosis of primary hyperparathyroidism and
symptoms associated with hypercalcemia. Furthermore,
parathyroid surgery is indicated in asymptomatic patients
with primary hyperparathyroidism that meet one or more
of the criteria in the revised guidelines of the Third
International Workshop on the Management of Asymp-
tomatic Primary Hyperparathyroidism that include serum
calcium >1.0mg/dL (0.25mmoL/liter) above normal range,
creatinine clearance reduced to <60mL/min, T-score <-
2.5 (in lumbar spine, total hip, femoral neck, or 33%
radius) and/or previous fracture fragility (use Z-scores in
premenopausal women and men younger than 50 years), age
<50, and inability to obtain continued medical surveillance
[1].
4.SurgicalTreatment
With the advent of improved preoperative localization
techniques, increased availability of IPM, and the predom-
inance of single-gland disease (85–96%) in patients with
primary hyperparathyroidism, targeted or limited parathy-
roidectomy has replaced conventional BNE as the standard
approach at most specialized surgical centers worldwide
[3–7]. Advantages of targeted parathyroidectomy include
improved cosmetic results with smaller incisions, decreased
pain, shorter operative time, ambulatory surgery, decreased
hospitalization, quick postoperative recovery, less frequent
injury to the recurrent laryngeal nerve, decreased post-
operative hypocalcemia, and comparable success rates to
conventional BNE [4–7].
Many techniques of focused parathyroidectomy have
been described that incorporate and share the common
aspects and principles of minimally invasive surgery, such
as less dissection, decreased operative time, less morbidity,
and comparable reported operative success to BNE ranging
from97% to99%. Fortargetedparathyroidectomyto besuc-
cessful, precise preoperative localization is essential. These
focused procedures are performed in patients with a single
parathyroid adenoma localized by preoperative sestamibi
and/or US through a central or lateral incision measuring
from2to4cm.Onlytheabnormalparathyroidglandisiden-
tiﬁedandexcised.IPMisusedbymostendocrinesurgeonsto
conﬁrm that no additional hypersecreting parathyroid tissue
remains. During this operation, blood is drawn to measure
parathyroid hormone levels at baseline and after excision
of a hyperfunctioning parathyroid gland. When IPM levels
decreaseby>50%10minutesafterglandexcision,thelimited
operation is completed. If a >50% drop does not occur,
either a double adenoma or 4-gland hyperplasia is present
and bilateral neck exploration is then performed. Under
general or local anesthesia, targeted parathyroidectomy can
be oﬀered to most patients in the outpatient setting. Patients
with known multiglandular disease (MGD) preoperatively
are not oﬀered this focused approach.
5.PreoperativeParathyroidLocalization
Preoperative localization of hyperfunctioning parathyroid
tissue is an essential component of focused parathyroidec-
tomy. Parathyroid localization has improved with a variety
of familiar imaging techniques including sestamibi scintig-
raphy, ultrasonography, and four-dimensional computed
tomography, which has the added dimension of changes
in perfusion of contrast over time compared to regular 3-
D CT. Comparisons of these diﬀerent imaging modalities
have shown the superiority of scintigraphy for preoperative
parathyroid localization. First reported in 1989, technetium
(99mTc) sestamibi is used for parathyroid scintigraphy as a
radiotracer injected intravenously where the patient’s neck is
later imaged with a gamma camera [21]. 99mTc sestamibi
consists of lipophilic cationic molecules. After intravenous
injection, the molecules are distributed throughout the cir-
culatory system, into cells by passive diﬀusion, and become
concentrated intracellularly in mitochondria. Approximately
two hours after injection, thyroid cells lose signiﬁcant ses-
tamibi uptake whereas abnormal parathyroid gland oxyphil
cells retain the marker in high mitochondrial concentrations
that assist in parathyroid adenoma localization. Sestamibi
has been regarded as the single best imaging modality for
parathyroid adenoma identiﬁcation over ultrasonography,
CT, and magnetic resonance imaging [22–24]. Notwith-
standing, this technology has its limitations. The radiotracer
provides only two-dimensional, planar images. Sestamibi
can localize 80% to 90% of single abnormal parathyroid
glands, but it is less sensitive in the diagnosis of MGD
[25–27]. Thyroid nodules or lymph nodes can also mimic
abnormal parathyroid glands and cause false-positive results
on sestamibi scans [28].
SPECT is currently used with increased frequency due
to the three-dimensional information it provides with an
improved sensitivity for the detection and localization
of hyperfunctioning parathyroid glands (Figure 1). SPECT
measures gamma radiation and obtains multiple angle
images of the neck and mediastinum and then merges all
cutstoreconstructathree-dimensionalimage.Theadvanced
contrast resolution of SPECT is the primary reason for its
superiority over other imaging methods. Multiple studies
have established the role and advantages of SPECT in
the improvement of parathyroid localization. In one of
the largest studies looking at SPECT in over 550 patients
with primary hyperparathyroidism, radiologists developed
a scoring system to predict parathyroid pathology based
on intensity and pattern of sestamibi uptake. Patients
with a SPECT image reading as “probable” or “deﬁnite”
for parathyroid adenoma had a positive predictive value
(PPV) of >94% for adenoma presence and correct laterality
localization upon review of surgical ﬁndings. Patients with
negative scans, however, had a higher rate of operative
failure. Multiglandular disease was still not well predicted
[29]. Investigators have also come to appreciate that using
a hybrid SPECT/CT scan can further enhance localization
by providing better resolution of surrounding structures.
The fusion of CT with SPECT images allows for the com-
bined anatomic information from CT and the physiologic4 International Journal of Molecular Imaging
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Figure 1: Coronal (a) and transverse (b) tomograms from a delayed phase SPECT in a patient with a left superior parathyroid adenoma
conﬁrmed at surgery.
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Figure 2: Left superior parathyroid adenoma with delayed washout. Delayed phase (a) coronal, (b) sagittal, and (c) transverse fused
SPECT/CT tomograms show a left superior parathyroid adenoma with a posterior location at the upper pole of the left thyroid lobe.
three-dimensional information from SPECT (Figure 2). This
SPECT/CT combination has the added beneﬁt of a more
precise anatomic localization of ectopic and mediastinal
parathyroid adenomas.
In a direct comparison study of sestamibi scintigraphy,
SPECT, and SPECT/CT in patients with severe primary
hyperparathyroidism, patients had either multinodular goi-
ters with unclear gland identiﬁcation by US, normal thyroid
glands with negative parathyroid localization by US, or
ectopic glands demonstrated by planar parathyroid scintig-
raphy [30]. All patients underwent the three imaging modal-
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only showed the presence of 14 probable hyperfunctioning
parathyroid glands (12 in eutopic, 2 in ectopic locations)
of 23 lesions localized at surgery (61%) whereas SPECT
showed the presence of 23 probable adenomas (9 eutopic,
14 ectopic), but only correctly identiﬁed the location of 14
out of 23 lesions (61%) with extreme precision. SPECT/CT,
however, identiﬁed the presence and correct location of
100% (all 23) of the lesions, and it was the only modality that
identiﬁed retrotracheal parathyroid glands in three diﬀerent
patients.
An evaluation of planar imaging, SPECT, and SPECT/CT
scintigraphy was performed on 98 patients with primary
hyperparathyroidism caused by single adenoma with no
previous neck surgery [31]. Each patient was subjected
to planar imaging, SPECT, and SPECT/CT at 15 minutes
and two hours after sestamibi injection. Surgical location
servedasthestandard.EarlySPECT/CTincombinationwith
any delayed (two-hour) imaging method was signiﬁcantly
superior to any single- or dual-phase planar or SPECT study
in regards to sensitivity and positive predictive value for
abnormal parathyroid localization. Parathyroid localization
had a sensitivity of 34% for single-phase early planar
images, 45% for single-phase delayed planar images, 57%
for dual-phase planar, 54% for single-phase early SPECT,
54% for single-phase delayed SPECT, and 62% for dual-
phase SPECT that increased to 73% sensitivity for dual-
phase studies with early SPECT/CT. Speciﬁcity and negative
predictive values remained constant across all modalities.
Localization with dual-phase acquisition was also found to
be more accurate than with single-phase 99mTc-sestamibi
scintigraphy for planar imaging, SPECT, and SPECT/CT.
This study concluded that dual-phase imaging with early
SPECT/CT should be incorporated into routine preoperative
planning for all patients with primary hyperparathyroidism.
Other studies have reported similar sensitivities, but
also impressive speciﬁcity for SPECT/CT in localizing
parathyroid adenomas. In one study comparing SPECT
and SPECT/CT in 61 patients with primary hyperparathy-
roidism, although the sensitivities of SPECT (71%) and
SPECT/CT (70%) were similar (P = .779), the speciﬁcity
of SPECT/CT (96%) was signiﬁcantly greater than that of
SPECT alone (48%; P = .006) [32]. In another report of 116
patients with single-gland disease, sensitivity for SPECT/CT
was 88%, for CT 70%, and for SPECT 59%. Speciﬁcity for
SPECT/CT was 99%, for SPECT 95%, and for CT 94% [33].
Both studies concluded that SPECT/CT fusion was superior
to the individual CT or SPECT images alone in localizing
parathyroid adenomas.
In a study of 28 patients undergoing reoperative surgery
for a “missed” parathyroid gland, SPECT/CT was able to
predict the exact position of the abnormal gland in 86%
of the patients whereas SPECT was successful in only
43% of cases (P<. 004). SPECT/CT detected all three
pathologic glands in ectopic positions [34]. Further reports
supported that the additional information provided by
hybrid SPECT/CT imaging often proved to be advantageous
in the detection and localization of ectopic parathyroid
adenomas [35]. Another population in which SPECT/CT
might prove beneﬁcial is patients with multinodular goiter
and primary hyperparathyroidism. In a study of 33 patients
with these two diagnoses, all study individuals underwent
preoperative sestamibi planar scintigraphy and SPECT (18
patients) or SPECT/CT (15 patients) after cervical ultra-
sound [36]. SPECT/CT showed higher sensitivity than
SPECT (87.5% versus 55.6%; P = .0001) and higher PPV
(87.5% versus 62.5%; P = .0022) for correctly identifying
the neck quadrant aﬀected by primary hyperparathyroidism;
the speciﬁcity trended toward SPECT/CT over SPECT,
but was not signiﬁcant (95.5% and 88.5%, resp.). The
report concluded that SPECT/CT is superior to SPECT
for preoperative imaging of patients with both primary
hyperparathyroidismandmultinodulargoiter,andshouldbe
a routine part of this population’s preoperative workup.
More studies concur that SPECT/CT oﬀers enhanced
ability to localize abnormal parathyroid glands above planar
scintigraphy or SPECT alone. In investigating the role of
SPECT/CT in the general oncologic patients, the functional
and anatomic imaging obtained from SPECT and CT has
been shown to be synergistic versus complementary, and
can signiﬁcantly contribute to more accurate localization of
parathyroid and other cancers [37]. While the SPECT/CT
can be technically challenging to perform and potentially
increase patient radiation doses, the beneﬁts of its improved
sensitivity and speciﬁcity can decrease need for future
conﬁrmatory imaging studies [33, 35].
6. Conclusion
Primary hyperparathyroidism is caused by a single parathy-
roidglandinupto96%ofcases.Focusedparathyroidectomy
is the preferred treatment of choice for this condition, and
scintigraphy is a principal method used for preoperative
parathyroid gland localization. SPECT is more useful than
planar imaging since it provides additional information
about the superior/inferior and anterior/posterior loca-
tion of abnormal parathyroid glands. Fusion of CT with
SPECT has the added beneﬁt of providing not only useful
anatomic information but functional assessment as well. For
patients with ectopic glands or patients facing reoperation,
SPECT/CT is particularly helpful for preoperative localiza-
tion and may become the preferred method of parathyroid
detection and localization in such clinical scenarios. Nev-
ertheless, the long-term clinical and economic beneﬁts of
SPECT and SPECT/CT, although promising, remain to be
determined.
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